Naloxegol Drug Utilization PASS

AZ agreed to conduct this post-authorization observational safety study to determine the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway, Sweden, and Germany

The overall research questions for this study are: 1) What are the demographic, clinical, and treatment characteristics (including dose) at baseline of patients prescribed naloxegol in real-world practice (including the use of naloxegol in non-indicated populations)? and 2) What are the treatment patterns of naloxegol utilization during follow-up? Primary objectives: 1 To describe the characteristics of patients prescribed naloxegol at time of first prescription (demographics, targeted comorbidities, targeted comedications, provider characteristics, and indication characteristics). 2 To describe any of the following treatment patterns: - Discontinuation of naloxegol (permanently during the observation period) - Switching from naloxegol to other drug(s) potentially used by patients with opioid induced constipation (OIC) - Prescription of other drug(s) potentially used by patients with OIC in the same period when naloxegol is prescribed (augmentation) - Restart in the prescription of naloxegol (after temporary discontinuation or treatment holiday) - Continuous treatment with naloxegol during the study period - Change in dosing Exploratory objective: 1. To identify predictors of length of naloxegol use